| Bioactivity | DLC-50 is a dual inhibitor for PARP-1 and HDAC-1 with IC50 of 1.2 nM and 31 nM. DLC-50 inhibits the proliferation of cancer cells MDA-MB-436, MDA-MB-231, and MCF-7 with IC50 of 0.3, 2.7 and 2.41 μM. DLC-50 induces apoptosis in MDA-MB-231, arrests the cell cycle at G2 phase[1]. |
| CAS | 2928537-98-6 |
| Formula | C28H32FN5O4S2 |
| Molar Mass | 585.71 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wu J, et al. Design, synthesis and antitumor activities of phthalazinone derivatives as PARP-1 inhibitors and PARP-1/HDAC-1 inhibitors[J]. Bioorganic Chemistry, 2024: 107556. |
DLC-50
CAS: 2928537-98-6 F: C28H32FN5O4S2 W: 585.71
DLC-50 is a dual inhibitor for PARP-1 and HDAC-1 with IC50 of 1.2 nM and 31 nM. DLC-50 inhibits the proliferation of can
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.